請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66946
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林文澧(Win-Li Lin) | |
dc.contributor.author | Chung-You Huang | en |
dc.contributor.author | 黃中佑 | zh_TW |
dc.date.accessioned | 2021-06-17T01:15:28Z | - |
dc.date.available | 2022-08-25 | |
dc.date.copyright | 2017-08-25 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-14 | |
dc.identifier.citation | [1] Fact Sheets by Cancer. (2017). Globocan.iarc.fr. Retrieved 19 April 2012, from http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
[2] He S, Nakada D, Morrison SJ. Morrison Annu. Mechanisms of Stem Cell Self-Renewal. Rev. Cell Dev. Biol. 2009;25:377–406. [3] Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-7. [4] Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-8. [5] Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J,and Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821-8. [6] Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444:761-5. [7] Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005;121:823-35. [8] O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-10. [9] Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339-44. [10] Fiddler IJ. Melanoma metastasis. Cancer Control. 1995;2(5):398-404. [11] Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012;29(2):1314-27. [12] Schmelzle T, Hall MN. TOR. a central controller of cell growth. Cell. 2000;103(2):253–62. [13] Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J. 2008;412(2):e3–5. [14] Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89(3):1025–78. [15] Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012;30 (10), 2100-2113. [16] Barton DE, Kwon BS, Francke U. Human tyrosinase gene, mapped to chromosome 11 (q14----q21), defines second region of homology with mouse chromosome 7. Genomics. 1988;3(1):17-24. [17] Evans JM, Donnelly L, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5. [18] Bowker SL, Majumdar S, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254–8. [19] Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33(2): 322–6. [20] Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009;46(4):279–84. [21] Currie CJ, Poole C, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–77. [22] Li D, Yeung S, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137(2):482–8. [23] Bodmer M, Meier C, Kra¨henbu¨hl S, Jick SS, Meier CR. Long-term Metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33(6):1304–8. [24] Jiralerspong S, Palla S, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297–302. [25] Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res. 2010;3(9):1077–83. [26] Berstein LM, Boyarkina M, Tsyrlina EV, Turkevich EA, and Semi-glazov VF. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with Metformin. Med Oncol. 2011;28(4):1260-3. [27] Miranda-Lorenzo I, Dorado J, Lonardo E, Alcala S, Serrano AG, Clausell-Tormos J, Cioffi M, Megias D, Zagorac S, Balic A, Hidalgo M, Erkan M, Kleeff J, Scarpa A, Sainz B Jr, Heeschen C. Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. Nat Methods. 2014;11(11):1161-9. [28] Min SO, Lee SW, Bak SY, Kim KS. Ideal sphere-forming culture conditions to maintain pluripotency in a hepatocellular carcinoma cell lines. Cancer Cell Int. 2015:15:95. [29] Pastrana E, Silva-Vargas V, Doetsch F. Eyes Wide Open: A Critical Review of Sphere-Formation as an Assay For Stem Cells. Cell Stem Cell. 2011; 8(5): 486–498. [30] Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder J-M, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2011;2:e199. [31] Petrachi T, Romagnani A, Albini A, Longo C, Argenziano G, Grisendi G, Dominici M, Ciarrocchi A, Dallaglio K. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget. 2017;8(4):6914-6928. [32] Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143-56. [33] Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12(11):767-75. [34] Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, Carbone A, Santinami M, Patuzzo R, Mina PD, Villa A, Pratesi G, Cossa G, Perego P, Daidone MG, Alison MR, Parmiani G, Rivoltini L, Castelli C. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol. 2010;130(7):1877-86. [35] Parmiani G. Melanoma Cancer Stem Cells: Markers and Functions. Cancers (Basel). 2016;8(3). [36] Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell property in melanomas. Cancer Res. 2005, 65, 9228–9237. [37] Lang, D., Masatolcarenhas, J.B., Shea, C.R. Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin. Dermatol. 2013, 32, 166–178. [38] Koshio, J., Kagama, H., Nozaki, K., Saida, Y., Tanaka, T., Shoji, N., Igarashi, N., Miura, S., Okajima, M., Watanabe, S., et al. DEAD/H (Asp-Glu-Ala-Asp/His) box polipeptide 3, X-linked I san immunogenic target of cancer stem cells. Cancer Immunol Immunother. 2013;62(10):1619-28. [39] Gedye C, Quirk J, Browning J, Svobodová S, John T, Sluka P, Dunbar PR, Corbeil D, Cebon J, Davis ID. Cancer/testis antigens can be immunological target in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother. 2009;58(10):1635-46. [40] Roudi R, Korourian A, Shariftabrizi A, Madjd Z. Differential expression of cancer stem cells markers ALDH1 and CD133 in various lung cancer subtypes. Cancer Investig. 2015, 33, 294–302. [41] Maccalli C, Volontè A, Cimminiello C, Parmiani G. Immunology of cancer stem cells in solid tumours. A review. Eur J Cancer. 2014;50(3):649-55. [42] Schatton T, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 2010;70(2):697-708. [43] Santini R, Vinci MC, Pandolfi S, Penachioni JY, Montagnani V, Olivito B, Gattai R, Pimpinelli N, Gerlini G, Borgognoni L, Stecca B. HEDGEHOG-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells. 2012;30(9):1808-18. [44] Desiderio V, Papagerakis P, Tirino V, Zheng L, Matossian M, Prince ME, Paino F, Mele L, Papaccio F, Montella R, Papaccio G, Papagerakis S. Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells. Oncotarget. 2015;6(1):71-84. [45] Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15(3):504-14. [46] Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011;8(2):97-106. [47] Matthew J. Martin, Robert Hayward, Amaya Viros, and Richard Marais. Metformin accelerates the growth of BRAF V600E -driven melanoma by upregulating VEGF-A. Cancer Discov. 2012; 2(4): 344–355. [48] Petrachi T, Romagnani A, Albini A, Longo C, Argenziano G, Grisendi G, Dominici M, Ciarrocchi A, Dallaglio K. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget. 2017;8(4):6914-6928. [49] Shiozawa Y, Nie B, Pienta KJ, Morgan TM, Taichman RS. Cancer stem cells and their role in metastasis. Pharmacol Ther. 2013;138(2):285-93. [50] Chang JC. Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltimore). 2016;95(1 Suppl 1):S20-5. [51] Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69(19):7507-11. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66946 | - |
dc.description.abstract | 背景:
癌幹細胞( Cancer Stem Cell( CSC))是指具有自我更新( Self-renewal)以及多細胞分化( Differentiation)等幹細胞( Stem cell) 能力的癌細胞。癌幹細胞目前被認為是造成癌症轉移、復發,或者對於化學治療、放射性治療產生抗藥性的主要原因之一。很多科學家希望能夠研究出殺死癌幹細胞的方法,以降低腫瘤抗藥性及轉移。在治療癌幹細胞的研究中,發現治療糖尿病的Metformin能有效抑制癌幹細胞。黑色素癌( Melanoma)的腫瘤中包含癌幹細胞,可以建立一個平台來測試治療癌症的方法以及研究癌幹細胞的特性。 目的: 尋求光學顯像技術來直接觀測探討Metformin在活體環境下是否能對黑色素癌幹細胞有抑制生長或殺死作用。 材料與方法: 在體外實驗部分,透過立體細胞培養技術探討Metformin對黑色素癌幹細胞的影響。在動物實驗部分,則使用多光子顯微鏡系統,來評估Metformin對雄性C57BL/6-C2J小鼠耳朵上的黑色素癌腫瘤的影響。 結果: 在細胞實驗部分,和先前研究成果一樣,Metformin的濃度越高則形成的癌細胞球團數量越少。在動物實驗方面,在經過16天治療後,治療組癌幹細胞的光學信號明顯減弱。結果顯示Metformin對黑色素癌幹細胞及癌腫瘤在經過一段時間治療後,有抑制腫瘤形成及成長作用。 結論: 光學顯微系統可觀測到短期Metformin 治療在活體和體外細胞實驗中能夠抑制黑色素癌幹細胞。 | zh_TW |
dc.description.abstract | Background:
Cancer stem cells ( CSCs) are cancer cells referred to have some stem cell capabilities, for example, self-renewal and multi-cellular differentiation. Cancer stem cells are now considered as one of the main causes for cancer metastasis, recurrence, and resistance to chemotherapy and radiotherapy. Many scientists have been developing methods to kill cancer stem cells to reduce tumor resistance or metastasis. Metformin, drug for type 2 diabetes, inhibiting cancer stem cell growth was shown in recent cancer research. Malignant melanoma contains cancer stem cells and it can be used to establish a platform for evaluating cancer treatment methods and characterizing cancer stem cells. Purpose: To evaluate the effect of Metformin on melanoma cancer stem cells by observing in vitro 3-D cell culture and in vivo murine with optical microscopy. Materials & Methods: In vitro experiment, we explored the effect of Metformin on melanoma cancer stem cells using 3D cell culture technique. In the animal experiment, we used a multi-photon imaging microscopy system to evaluate the effect of Metformin in ear melanoma of male C57BL/6-C2J mice. Results: The in-vitro results showed that the number of cell spheres was less for a higher concentration of Metformin and the results are similar to the papers published by other groups. In the animal experiment, the preliminary results showed that the signal of cancer stem cells for the treated group is less than the control group after 16 days of treatment. Conclusion: The overall results suggested that optical microscopy can be used to observe short-term Metformin treatment inhibiting melanoma cancer stem cells both in vitro and in vivo studies. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:15:28Z (GMT). No. of bitstreams: 1 ntu-106-R04548067-1.pdf: 4851005 bytes, checksum: 41e7aa9442ebb28c565576abc6f6dce8 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書 #
誌謝 i 中文摘要 ii ABSTRACT iii 目錄 v 圖目錄 viii 表格目錄 xiv 第 1 章 緒論 1 1.1 癌幹細胞 1 1.1.1 癌幹細胞的定義 2 1.2 Metformin 2 1.2.1 Metformin活化AMPK 3 1.2.2 降低胰島素濃度 4 1.2.3 其他機制 4 1.3 黑色素癌( Melanoma) 5 1.3.1 黑色素癌幹細胞的標記 5 1.4 研究動機 6 第 2 章 材料與方法 7 2.1 細胞 7 2.1.1 細胞來源 7 2.1.2 三維立體細胞培養技術 8 2.2 藥劑使用與配製 10 2.2.1 化學治療藥物 10 2.2.2 Metformin藥物 11 2.2.3 動物麻醉劑 12 2.3 癌幹細胞的分離與驗證 12 2.3.1 化學藥物治療測試 13 2.4 體外細胞實驗 13 2.5 影像擷取系統 14 2.5.1 Leica TCS SP5共軛焦顯微鏡系統( Confocal Microscopy System) 14 2.5.2 ZEISS LSM 710非線性共軛焦顯微鏡 14 2.6 動物實驗 15 2.6.1 動物來源 15 2.6.2 黑色素癌模型 15 2.6.3 實驗分組與治療時程規劃 15 2.6.4 影像擷取及分析 16 第 3 章 結果 18 3.1 癌幹細胞的分離與驗證結果 18 3.1.1 Sphere-forming Assays結果 19 3.1.2 化學治療藥物驗證 23 3.2 不同Metformin濃度的影響 26 3.2.1 Metformin對黑色素癌幹細胞的作用 26 3.2.2 在Doxorubicin固定濃度下,不同濃度Metformin對黑色素癌幹細胞影響 27 3.3 多光子與共軛焦系統的比較 31 3.4 動物實驗結果 33 3.4.1 動物實驗前置測試結果 33 3.4.2 活體小鼠動物光學影像實驗結果 35 第 4 章 討論 52 第 5 章 結論與未來方向 54 5.1 癌幹細胞的分離與驗證 54 5.2 體外癌細胞實驗 54 5.3 活體影像擷取 54 5.4 未來方向 55 縮寫表 56 參考文獻 57 | |
dc.language.iso | zh-TW | |
dc.title | 以光學顯微術來探討Metformin對黑色素癌幹細胞的治療效用 | zh_TW |
dc.title | Investigating the Therapeutic Effect of Metformin on Melanoma Cancer Stem Cells Using Optical Microscopy | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張富雄(Fu-Hsiung CHANG),謝銘鈞(Ming-Jium Shieh) | |
dc.subject.keyword | 癌幹細胞,自我更新,Metformin,黑色素癌,多光子顯微鏡系統, | zh_TW |
dc.subject.keyword | self-renewal,cancer stem cells,Metformin,melanoma,multi-photon microscopy system, | en |
dc.relation.page | 63 | |
dc.identifier.doi | 10.6342/NTU201702935 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-14 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 4.74 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。